| Date | Title | Description |
| - | Precision BioSciences Raises $110M to Advance ARCUS Genome Editing Programs | DURHAM, North Carolina, USA, June 26 2018 –Precision BioSciences today announced the closing of an oversubscribed $110M Series B financing to further product development efforts based on its ARCUS® genome editing platform. The financing was... |
| - | Finch Therapeutics Completes Enrollment in Potentially Pivotal Trial of CP101, an Investigational Oral Full-Spectrum Microbiota® Therapy for the Prevention of Recurrent C. difficile Infection | – 206 patients randomized at 51 centers in a multinational, placebo-controlled trial
– Topline data expected at the end of Q2 2020
Somerville, MA (January 8, 2020) — Finch Therapeutics Group, Inc. (“Finch”), a clinical-stage microbiome th... |
| - | OSSIO Secures $22 Million in Financing | Proceeds to Be Used for US Commercialization and Operational Expansion
WOBURN, MA., March 11, 2019 — OSSIO, an orthopedic fixation company, today announced the closing of $22 million in equity financings led by OCV Partners, a Los Angeles ... |
| - | Hemi Zucker to Join OCV Management as Managing Principal | LOS ANGELES – OCV Management LLC (“OCV”), a technology investor based in Los Angeles, announced today that Nehemia (“Hemi”) Zucker will be joining the firm as Managing Principal starting on January 1, 2018. Until such date, Hemi will contin... |
| - | SafeBreach Raises $19 Million to Expand Channels, Accelerate Product Development | Experiencing rapid customer growth, the industry’s leading provider of breach-and-attack simulation will use the funding to accelerate the development of new product capabilities and services, expand strategic partnerships and grow its chan... |
| - | OCV Partners Participates in Finch Therapeutics’ Oversubscribed $90 Million Financing to Advance its Pipeline of Investigational Oral Microbiome Drugs | Proceeds to support the advancement of lead candidate through the final stages of clinical development for recurrent C. difficile infection, and the advancement into the clinic of programs for autism spectrum disorder and chronic hepatitis ... |
| - | Finch Therapeutics Raises $53 Million to Advance Microbiome-Based Therapies for Recurrent C. Difficile, Autism and other Disease Areas | Somerville, MA (August 22, 2019) — Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the completion of a $53 million Series C financing. The financing comes from new investors including OCV Pa... |
| - | OSSIO Receives FDA 510(k) Clearance for OSSIOfiber® Hammertoe Fixation System | Complete Offering of Implant Sizes and Shapes Provides Surgeons and their Patients an Intelligent Bone Regeneration Alternative to Metal Fixation
WOBURN, Mass — OSSIO, Inc., an orthopedic fixation company, today announced that its OSSIOfib... |
| - | OCV Partners Assist Portfolio Company Social Native in Acquiring Olapic to Create Next-Gen Creative Optimization Platform | September 29, 2020 03:24 PM Eastern Daylight Time |
| - | Invoice2go Raises $10 Million, Attracting New and Existing Investors, and Hemi Zucker from OCV Partners to join the Board of Directors | REDWOOD CITY, Calif., Sept 11, 2018 — Invoice2go announces it has closed a $10 million equity round led by OCV Partners, with additional participation from existing investors Accel and Ribbit Capital. Hemi Zucker of OCV Partners joins the I... |
| - | OCV Partners Co-leads By Heart’s $70M Series A Financing Ahead of First Product Launch in 2021 | Lead Investors Include Polaris Partners, D1 Capital Partners, and OCV Partners in the Over-Subscribed Round; Former Pfizer Baby Nutrition Leader, as well as Former CEO of J2 Global (What to Expect, BabyCenter and Everyday Health) Join the B... |
| - | Museum of Ice Cream Founders Launch Figure8 with Series A to Transform How Millennials and Gen-Z Connect With Spaces and Each Other | Funding led by Elizabeth Street Ventures, Maywic Select Investment, and OCV Partners
New York, NY (August 14, 2019) — Founders of Museum of Ice Cream, Maryellis Bunn and Manish Vora, launch Figure8, an experience-first development company.... |